Thursday, October 11, 2012
Publication and contact
RNA profiling to determine
prognosis in multiple sclerosis (MS)
Studies of patient samples
identified a transcriptional signature that could help determine MS
prognosis. Microarray data were generated for peripheral blood mononuclear
cells (PBMCs) isolated from 363 patients with MS who were previously
untreated or who had received interferon-b (IFNB;
IFN-b) or Copaxone
acetate. Unsupervised computational clustering of the subgroup
of 141 previously untreated patients identified 2 distinct gene expression
signatures that were correlated with significantly different rates of disease
activity (Cox proportional hazard ratio 0.6; p=0.0077). Next steps
include performing transcriptional analysis of subsets of purified blood
Copaxone glatiramer acetate
is marketed by Teva Pharmaceutical Industries Ltd. to
Biogen Idec Inc. markets Avonex
interferon beta-1a, Bayer AG markets Betaseron
interferon beta-1b and the Merck Serono S.A. division of Merck KGaA and Pfizer Inc. market Rebif
interferon beta-1a to treat MS.
Published online Oct. 11, 2012
status not applicable
Ottoboni, L. et al. Sci.
published online Sept. 26, 2012;
Contact: Philip L. De Jager, Brigham and Women's Hospital,
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]